Published in Vaccine Weekly, August 24th, 2005
Twinject, an epinephrine auto-injector indicated for the emergency treatment of severe allergic reactions (anaphylaxis), was approved by Health Canada in 2003. Two dosages are now approved for self-administration, 0.3 mg and 0.15 mg.
Anaphylaxis is a severe, life-threatening systemic allergic reaction triggered by exposure to one or more various antigens, including foods, insect stings, drugs, and latex products. Up to 43 million people in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.